Free tool
FAERS Monitor: Baxfendy
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219878 or its brand name (Baxfendy, Baxdrostat). Reports on generic versions are filed under their own applications.
Reports
273
Serious
83
30% of reports
Hospitalization
33
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hyponatraemia26
- dizziness22
- muscle spasms21
- hyperkalaemia19
- blood potassium increased17
- blood sodium decreased14
- glomerular filtration rate decreased14
- headache14
- blood pressure increased12
- nausea12
- blood pressure decreased11
- hypotension10
- hypertension9
- blood creatinine increased7
- fatigue7
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2026 | 273 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,886 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| glomerular filtration rate decreasedSignal | 14 | 87.9 | 52.7 | 1,117 |
| blood potassium increasedSignal | 17 | 80.8 | 51.0 | 1,261 |
| blood sodium decreasedSignal | 14 | 57.3 | 34.4 | 719 |
| hyperkalaemiaSignal | 19 | 41.8 | 27.1 | 717 |
| hyponatraemiaSignal | 26 | 35.6 | 24.7 | 842 |
| blood pressure decreasedSignal | 11 | 12.8 | 7.1 | 108 |
| muscle spasmsSignal | 21 | 8.8 | 5.8 | 139 |
| blood creatinine increasedSignal | 7 | 8.3 | 4.0 | 38 |
| blood pressure increasedSignal | 12 | 6.0 | 3.5 | 46 |
| hypotensionSignal | 10 | 3.8 | 2.1 | 18 |
| dizzinessSignal | 22 | 3.4 | 2.3 | 36 |
| hypertensionSignal | 9 | 3.3 | 1.7 | 12 |
| headache | 14 | 1.7 | 1.0 | 4 |
| nausea | 12 | 1.2 | 0.7 | 0 |
| fatigue | 7 | 0.7 | 0.3 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.